KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Debt: 2018-2024

Historic Total Debt for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to $7.6 billion.

  • Royalty Pharma's Total Debt rose 17.59% to $8.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 billion, marking a year-over-year increase of 17.59%. This contributed to the annual value of $7.6 billion for FY2024, which is 24.08% up from last year.
  • Per Royalty Pharma's latest filing, its Total Debt stood at $7.6 billion for FY2024, which was up 24.08% from $6.1 billion recorded in FY2023.
  • Royalty Pharma's 5-year Total Debt high stood at $7.6 billion for FY2024, and its period low was $5.9 billion during FY2020.
  • Over the past 3 years, Royalty Pharma's median Total Debt value was $7.1 billion (recorded in 2022), while the average stood at $7.0 billion.
  • In the last 5 years, Royalty Pharma's Total Debt dropped by 13.79% in 2023 and then rose by 24.08% in 2024.
  • Yearly analysis of 5 years shows Royalty Pharma's Total Debt stood at $5.9 billion in 2020, then grew by 21.22% to $7.2 billion in 2021, then fell by 1.22% to $7.1 billion in 2022, then fell by 13.79% to $6.1 billion in 2023, then grew by 24.08% to $7.6 billion in 2024.